Multi-Parametric Radiomic Model to Predict 1p/19q Co-Deletion in Patients with IDH-1 Mutant Glioma: Added Value to the T2-FLAIR Mismatch Sign.
1p/19q co-deletion
T2-FLAIR mismatch
deep learning
diffuse glioma
radiogenomic
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
07 Feb 2023
07 Feb 2023
Historique:
received:
13
12
2022
revised:
28
01
2023
accepted:
28
01
2023
entrez:
25
2
2023
pubmed:
26
2
2023
medline:
26
2
2023
Statut:
epublish
Résumé
The T2-FLAIR mismatch sign has shown promise in determining IDH mutant 1p/19q non-co-deleted gliomas with a high specificity and modest sensitivity. To develop a multi-parametric radiomic model using MRI to predict 1p/19q co-deletion status in patients with newly diagnosed IDH1 mutant glioma and to perform a comparative analysis to T2-FLAIR mismatch sign+. In this retrospective study, patients with diagnosis of IDH1 mutant gliomas with known 1p/19q status who had preoperative MRI were included. T2-FLAIR mismatch was evaluated independently by two board-certified neuroradiologists. Texture features were extracted from glioma segmentation of FLAIR images. eXtremeGradient Boosting (XGboost) classifiers were used for model development. Leave-one-out-cross-validation (LOOCV) and external validation performances were reported for both the training and external validation sets. A total of 103 patients were included for model development and 18 patients for external testing validation. The diagnostic performance (sensitivity/specificity/accuracy) in the determination of the 1p/19q co-deletion status was 59%/83%/67% (training) and 62.5%/70.0%/66.3% (testing) for the T2-FLAIR mismatch sign. This was significantly improved ( The proposed radiomic model provides much needed sensitivity to the highly specific T2-FLAIR mismatch sign in the determination of the 1p/19q non-co-deletion status and improves the overall diagnostic performance of neuroradiologists when used as an assistive tool.
Identifiants
pubmed: 36831380
pii: cancers15041037
doi: 10.3390/cancers15041037
pmc: PMC9954034
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NCI NIH HHS
ID : P50 CA211015
Pays : United States
Références
Radiology. 2017 Aug;284(2):316-331
pubmed: 28723281
J Clin Oncol. 2013 Jan 20;31(3):337-43
pubmed: 23071247
Eur Radiol. 2020 Feb;30(2):877-886
pubmed: 31691122
PLoS One. 2012;7(3):e32764
pubmed: 22427879
J Neurooncol. 2018 Nov;140(2):297-306
pubmed: 30097822
Int J Comput Assist Radiol Surg. 2018 Apr;13(4):563-571
pubmed: 29270916
Radiology. 2016 Sep;280(3):880-9
pubmed: 27326665
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
J Clin Oncol. 2006 Jun 20;24(18):2715-22
pubmed: 16782911
Eur J Nucl Med Mol Imaging. 2013 Jan;40(1):133-40
pubmed: 23064544
AJNR Am J Neuroradiol. 2020 Nov;41(11):1982-1988
pubmed: 32912874
Sci Rep. 2015 Aug 17;5:13087
pubmed: 26278466
Clin Cancer Res. 2017 Oct 15;23(20):6078-6085
pubmed: 28751449
Neuro Oncol. 2015 Sep;17(9):1188-98
pubmed: 26250565
Neuro Oncol. 2021 Aug 2;23(8):1215-1217
pubmed: 34185090
BMC Cancer. 2020 May 20;20(1):450
pubmed: 32434559
J Neuroimaging. 2022 Nov;32(6):1153-1160
pubmed: 36068184
Front Oncol. 2021 Nov 23;11:601425
pubmed: 34888226
Neuro Oncol. 2020 Jul 7;22(7):936-943
pubmed: 32064507
AJNR Am J Neuroradiol. 2018 Apr;39(4):687-692
pubmed: 29519793
Front Oncol. 2021 Jul 06;11:616740
pubmed: 34295805
Neuro Oncol. 2017 Jun 1;19(6):862-870
pubmed: 28339588
Brain Tumor Pathol. 2016 Jul;33(3):175-82
pubmed: 26849373
AJNR Am J Neuroradiol. 2019 Mar;40(3):426-432
pubmed: 30705071
Cancer Res. 2009 Dec 15;69(24):9157-9
pubmed: 19996293
Neurooncol Adv. 2020 Jan 10;2(1):vdaa004
pubmed: 32642675
IEEE EMBS Int Conf Biomed Health Inform. 2021 Jul;2021:
pubmed: 35813219
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Int J Mol Sci. 2020 Oct 27;21(21):
pubmed: 33121211
Radiology. 2020 Jan;294(1):160-167
pubmed: 31714193
Acta Neurochir (Wien). 2001 Dec;143(12):1195-203
pubmed: 11810382